How big is Entrada Therapeutics, Inc.?

As of Jun 18, Entrada Therapeutics, Inc. has a market capitalization of 273.64 million and reported net sales of 172.22 million and net profit of 24.78 million over the latest four quarters.

As of Jun 18, Entrada Therapeutics, Inc. has a market capitalization of 273.64 million, classifying it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 172.22 million, while the sum of Net Profit for the same period is 24.78 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 428.68 million and Total Assets at 526.32 million.

What does Entrada Therapeutics, Inc. do?

Entrada Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $21 million and a net profit of -$17 million. It has a market cap of $273.64 million and key metrics include a P/E ratio of 13.00 and a return on equity of 5.94%.

Overview: <BR>Entrada Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 21 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -17 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 273.64 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 13.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.90 <BR>Return on Equity: 5.94% <BR>Price to Book: 0.66 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Should I buy, sell or hold Entrada Therapeutics, Inc.?

Is Entrada Therapeutics, Inc. overvalued or undervalued?

As of August 6, 2025, Entrada Therapeutics, Inc. is considered risky and overvalued with a high P/E ratio of 13, a low price to book value of 0.76, negative EV to EBITDA and EV to EBIT ratios, and a year-to-date stock performance of -67.9% compared to the S&P 500's 12.22% return.

As of 6 August 2025, the valuation grade for Entrada Therapeutics, Inc. has moved from fair to risky, indicating a more cautious outlook on the stock. The company appears to be overvalued, given its P/E ratio of 13, which is relatively high compared to its peers, such as Avid Bioservices, Inc. with a P/E of -5.25 and Alector, Inc. at -2.52. Additionally, Entrada's price to book value stands at 0.76, suggesting that the market values the company less than its net assets, which is a concerning sign for potential investors.<BR><BR>The EV to EBITDA ratio of -7.68 and EV to EBIT of -14.66 further highlight the company's struggles in generating earnings relative to its enterprise value, reinforcing the notion of overvaluation. In terms of stock performance, Entrada Therapeutics has significantly underperformed against the S&P 500, with a year-to-date return of -67.9% compared to the index's 12.22%. This stark contrast in returns underscores the challenges the company faces in the current market environment.

Is Entrada Therapeutics, Inc. technically bullish or bearish?

As of July 17, 2025, Entrada Therapeutics is in a bearish technical trend with moderate strength, underperforming the S&P 500 significantly, showing a year-to-date return of -67.9% compared to the S&P 500's 12.22%.

As of 17 July 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance is bearish with moderate strength. The weekly MACD is mildly bullish, but the monthly MACD and KST are bearish, indicating a lack of strong upward momentum. The daily moving averages are bearish, and both the weekly and monthly Bollinger Bands and OBV are mildly bearish. The Dow Theory shows a mildly bearish stance on the weekly timeframe. <BR><BR>In terms of returns, Entrada Therapeutics has significantly underperformed the S&P 500, with a year-to-date return of -67.9% compared to the S&P 500's 12.22%, and a one-year return of -59.34% versus 17.14% for the benchmark.